Contact

Category: GSK

  • GSK shares jump after settlement of 80,000 Zantac lawsuits in U.S By Reuters

    •

    Investor Empires

    (Reuters) – GlaxoSmithKline shares rose 6 percent on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States alleging that the discontinued heartburn drug Zantac causes cancer. The agreement, announced on Wednesday, was well below some analysts’ estimates, including JPMorgan’s forecast…

  • GSK to seek dismissal of Florida case against heartburn drug Zantac By Reuters

    •

    Investor Empires

    (Reuters) – British drugmaker GSK said on Friday it will seek to dismiss an upcoming Zantac lawsuit in Florida where plaintiffs alleged the company’s discontinued heartburn drug caused prostate cancer. The move follows a Florida court ruling Thursday in favor of GlaxoSmithKline and other defendants that threw out expert testimony…

  • GSK slides 6% after US CDC narrows scope of RSV shots By Reuters

    •

    Investor Empires

    (Reuters) – GlaxoSmithKline shares fell more than 6% on Thursday, a day after the U.S. public health agency narrowed its recommendation for the use of all respiratory syncytial virus (RSV) vaccines and suspended recommending their use in people under 60. The US Centers for Disease Control and Prevention (CDC) said…

  • GSK raises full-year profit forecast, says first-half will see stronger sales By Reuters

    GSK raises full-year profit forecast, says first-half will see stronger sales By Reuters

    •

    bitlyfool

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some or all of your investment amount, and may not be suitable for all investors. Cryptocurrency prices are highly volatile and may be affected by external factors such as financial, regulatory or political events.…